ストックスクリーナーアプリを入手
328.16
0.93%
-3.08
アフターアワーズ：
324.01
-4.15
-1.26%
前日終値:
$331.24
開ける：
$331.61
24時間の取引高:
1.48M
Relative Volume:
1.04
時価総額：
$43.35B
収益：
$3.21B
当期純損益:
$43.57M
株価収益率:
1,364.49
EPS:
0.2405
ネットキャッシュフロー:
$221.36M
1週間 パフォーマンス:
-2.93%
1か月 パフォーマンス:
-19.25%
6か月 パフォーマンス:
-23.35%
1年 パフォーマンス:
+17.94%
1日の値動き範囲:
$326.51
$340.07
1週間の範囲:
$326.51
$355.49
52週間の値動き範囲:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Insider Trends: Should value investors consider Alnylam Pharmaceuticals Inc2025 AllTime Highs & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Finviz
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 49% Undervaluation? - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Revenue Outlook And Long Term Growth Targets - simplywall.st
Alnylam Pharmaceuticals (BIT:1ALNY) Price Target Decreased by 11.40% to 411.81 - Nasdaq
Alnylam Pharmaceuticals (ALNY): Investor Outlook with a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd - MarketBeat
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Receives Analyst Rating Update fr - GuruFocus
Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity? - simplywall.st
Morgan Stanley Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
ALNY: Morgan Stanley Adjusts Price Target Amidst Equal-Weight Ra - GuruFocus
H.C. Wainwright raises Alnylam Pharmaceuticals stock price target on TTR franchise potential - Investing.com Canada
Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $510.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Buy Rating on ALNY, Lowers Price T - GuruFocus
What analysts say about Alnylam Pharmaceuticals Inc. stockGold Moves & Safe Swing Trade Setups - Mfd.ru
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy - Finviz
What Alnylam Pharmaceuticals (ALNY)'s Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders - simplywall.st
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results - Chartmill
Whale Trades: Should I hold or sell Alnylam Pharmaceuticals Inc nowWeekly Profit Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Barclays Initiates Coverage on Alnylam Pharmaceuticals (ALNY) wi - GuruFocus
Street Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividendQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
J. Safra Sarasin Holding AG Has $4.34 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile - Chartmill
Federated Hermes Inc. Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook - Intellectia AI
Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression - Finviz
Aug Shorts: Is Alnylam Pharmaceuticals Inc impacted by rising rates2025 Earnings Impact & Safe Investment Capital Preservation Plans - baoquankhu1.vn
EFG Asset Management North America Corp. Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What are analysts’ price targets for Alnylam Pharmaceuticals Inc.Weekly Gains Summary & Stepwise Entry and Exit Trade Signals - mfd.ru
The Five Minute Read - Lowell Sun
Mitsubishi UFJ Trust & Banking Corp Sells 8,273 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wealth Enhancement Advisory Services LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2026 Revenue Guidance Signals Strong Growth Potential - simplywall.st
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Jennison Associates LLC Has $139.02 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Baillie Gifford & Co. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Nanomedicine Market Reached USD 169.51 Billion in 2024, to Reach - openPR.com
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Technical Reactions to ALNY Trends in Macro Strategies - Stock Traders Daily
RBC Capital Maintains Rating but Lowers Alnylam Pharmaceuticals (ALNY) Price Target | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $376.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $465.00 at Royal Bank Of Canada - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
1.99%
1.08%
大文字化:
|
ボリューム (24 時間):